Ziv-aflibercept in combination with FOLFIRI for the second-line treatment of patients with metastatic colorectal cancer: Third interim safety data from the global aflibercept safety and quality-of-life program (ASQoP and AFEQT studies).

Roberto Bordonaro(Ospedale Garibaldi), Julien Taı̈eb(Hôpital Européen Georges-Pompidou), Evaristo Maiello(Casa Sollievo della Sofferenza), Emmanuelle Dochy(Sanofi (Belgium)), Chiara Zilocchi(Sanofi (Italy)), Anne Thomas(Leicester Royal Infirmary), Pilar Alfonso, Giovanni Luca Frassineti, Giuseppe Aprile(Ospedale Santa Maria della Misericordia di Udine), Alberto F. Sobrero(Ospedale Policlinico San Martino), Libero Ciuffreda(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Rosario V. Iaffaioli(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Hendrik Kroening, Yan Moore(Sanofi (United States)), Gérard Lledo(American Society of Clinical Oncology), Sandrine Brette
Journal of Clinical Oncology
May 20, 2014
10.1200/jco.2014.32.15_suppl.e14562
Cited by 0

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
|The Lancet Oncology|2016|914
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet|2023|701
Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer
|Journal of Clinical Oncology|2012|434